Rhett Wilkerson: Biosimilars and Patient Costs for Cancer Care

Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses the role biosimilars have to play in reducing patient costs. 
October 28, 2019


Yeah, absolutely. And we've already seen that as well. A lot of the insurance companies are starting to dictate which biosimilars we switch to and when. I think it's a great benefit to the patient as well if we can find them something that is going to do the job as well and is appropriate and payable. You know, we're interested in in pursuing that option as well for the patients.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.